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Background: Radical prostatectomy (RP) is a common treatment for prostate cancer (PCa). Morbidity, mortality
and pathological outcomes may be superior in academic institutions. One explanation may be the involvement of
oncology fellowship trained urologists within academic institutions. The literature examining pathological outcomes
often lacks individual surgeon data. The objective of this study was to compare pathological outcomes following RP
between fellowship trained and non-fellowship trained urologists.
Methods: Population-based, retrospective chart review of men diagnosed with PCa between 2003 and 2008,
the majority treated with open approach RP (>99%). Pathological outcomes were compared between oncology
fellowship trained academic (FTA), non-fellowship trained academic (NFTA) and non-academic (NA) urologists.
Relationships with pathological outcomes were examined utilizing multivariable logistic regression.
Results: 83.1% of eligible patients were included in our analysis resulting in 1075 patients. In multivariable analysis,
surgeon group was an independent predictor of positive surgical margin (PSM) (p < 0.0001). NFTA and NA urologists
were more likely to have PSM compared to FTA urologists (OR 2.50; 95% CI: 1.44 - 4.35 and OR 2.10; 95% CI: 1.53 - 2.88,
respectively). However, the proportion of PSM between NFTA and NA urologists was not significant (p = 0.492). In
addition, pathological stage (p = 0.0004), Gleason sum (p < 0.0001), and surgeon volume (p = 0.017) were associated
with PSM. Limitations include retrospective design and lack of clinical and functional outcomes.
Conclusions: Uro-oncology fellowship trained surgeons had significantly lower rates of PSM than non-fellowship
trained surgeons in this population based cohort. This study demonstrates the importance of surgeon-related
variables on pathological outcomes and highlights the value of additional urologic oncology fellowship training.
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Prostate adenocarcinoma (PCa) is a prevalent disease with
an estimated 256,600 cases expected to be diagnosed in
Canada and the US in 2014 alone [1,2]. A significant
proportion of patients diagnosed with PCa will undergo a
radical prostatectomy (RP). Although a complex issue, it is
generally believed that hospitals and surgeons with in-
creased caseloads have reduced rates of post-operative
complications, including lower urinary complications and
improved oncological outcomes [3-12]. Furthermore,* Correspondence: harvey.quon@cancercare.mb.ca
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unless otherwise stated.numerous clinical and pathological factors have been
shown to be associated with disease recurrence following
RP including clinical stage, biopsy Gleason sum, final
Gleason sum, pre-treatment prostate-specific antigen
(PSA) and surgical margin status [13,14]. Positive surgical
margins (PSM) are associated with increased risks of
biochemical recurrence after RP and currently represent a
potentially modifiable variable to improve oncological
control [7,13,15-18]. Furthermore, PSM is one of the very
few quality indicators of surgery. It has previously been
shown that substantial variation exists in PSM rates
between individual surgeons. Even among experienced
surgeons, others have shown that PSM rates range fromtd. This is an Open Access article distributed under the terms of the Creative
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that the individual surgeon may be an independent risk
factor for PSM [5,7].
Earlier studies have demonstrated that after adjusting for
annual hospital caseload, better outcomes were achieved
following RP in academically affiliated institutions [19].
Specifically, RP performed in academic institutions were
associated with fewer blood transfusions, fewer post-
operative complications and shorter lengths of stay in
hospital [20]. The authors postulated that this might be
due to increased caseloads, continual peer-review through
the decision-making process and/or multi-disciplinary
team approaches to patients. Unfortunately, this study was
limited by lack of individual surgeon data and information
on clinic-pathological outcomes. Another potential reason
for superior outcomes may be the involvement of uro-
oncology trained clinicians within these institutions. Gen-
erally speaking, supporters of sub-specialization claim that
fellowship training translates into improved outcomes.
Urologic oncology fellowship programs provide intensive
training with a concentrated surgical experience focusing
on oncological theory and skills. In fact, it has been shown
in a small prospective, cohort study, that fellowship train-
ing can abbreviate the learning curve associated with RP
[21]. However, to the authors’ knowledge there have been
no studies investigating the impact of oncology fellowship
training on pathological outcomes following RP in a
population-based cohort.
It is well documented that PSM have negative prognostic
implications including increased rates of biochemical
recurrence and disease progression [7,13,15-18]. Thus,
PSM may be used as a surrogate measure of oncological
outcomes. As such, we sought to determine the impact of
urological oncology fellowship training on PSM rates
following RP.
Methods
The study was approved by the University of Manitoba
Research Ethics Board. As this was a retrospective study,
informed consent was not obtained from patients.
Study population
We performed a retrospective population-based study,
utilizing a provincial cancer registry to identify all men
who were diagnosed with PCa between 2003 and 2008
in whom the vast majority were treated with open
approach RP (>99%). A small number of RP’s were per-
formed laparoscopically (estimated, approximately <10)
and were included within this study cohort. Robotic
assisted RP were not available at the time of our study.
All malignancies are mandatorily reported to the provincial
cancer registry. The pathological records of these patients
are stored in a central location and were reviewed
manually.Data collection
For all patients, age, year of diagnosis of prostate cancer,
year of surgery, surgeon characteristics, and pathological
outcomes following RP were obtained. Surgeons were
classified as either: fellowship trained academic (FTA),
non-fellowship trained academic (NFTA) or non-academic
(NA) urologists based on the highest level of training
achieved. For the purpose of our study, fellowship training
refers exclusively to surgeons who completed accredited
Urologic Oncology programs according to the Society of
Urological Oncology. Academic urologists who completed
other fellowships (e.g. endourology) were considered as
‘non-fellowship’ for the purpose of this study. A hospital
was considered an academic centre if associated with an
accredited residency training program. There was no cross-
over between surgeons and their respective institutions.
No non-academic surgeons had accredited oncology
fellowship training. Pathological reports were reviewed and
the following variables were identified: Gleason sum,
margin positivity, and lymph node status. Positive margins
were defined as cancer at the inked resection margin.
Statistical analysis
The primary purpose of our study was to evaluate the
relationship between the PSM rates following RP and
surgeon training. Surgeons were grouped into three cat-
egories as previously described (FTA, NFTA, and NA).
Age was analyzed as a continuous variable. Annual vol-
ume was not linearly related to the outcome. As such,
annual surgeon volume was analyzed as a categorical
variable, defined as the average number of cases per year
over the study period (low: <10 cases/year, medium: 10–20
cases/year, high: >20 cases/year). As these were patients di-
agnosed with PCa between 2003 and 2008, the patients
may have undergone their treatment in a different year
than they were diagnosed. Thus, the annual volume was
assessed over 2004–2008 as a representation of the
surgeons RP practice. Pathological outcomes that were
analyzed as categorical variables included: Gleason sum
(≤6, 7 (3 + 4, 4 + 3), ≥8) and stage (pT2, pT3a, pT3b, pT4).
Nodal status was categorized as presence or absence of
pathologically involved lymph nodes.
Logistic regression was conducted to examine factors
related to positive margins following radical prostatec-
tomy. The surgeon group variable (FTA, NFTA, NA), as
well as the covariates of surgeon volume, pathological
stage, Gleason sum, and node status were examined as po-
tential predictors of PSM. Associations between predictor
variables of interest and PSM were initially evaluated with
univariable models. Variables were considered significant
and eligible for inclusion in a multivariable model if
p-values ≤0.2. This p-value was chosen to help prevent
the inadvertent exclusion of variables whose effect may be
masked by another variable (i.e. the effect of a predictor
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Correlation between variables was assessed by Spearman’s
Rank correlation test, variance inflation factor and toler-
ance statistics. Correlation coefficients ≥0.80, variance
inflation factor values ≥10, and/or tolerance values ≤0.2
were considered indicative of multi-colinearity. All signifi-
cant, non-correlated predictor variables were considered
for inclusion in a multivariable model using a manual for-
ward, then backward selection. Variables were considered
significant if p-value ≤0.05. All model building analyses
were performed with Stata statistical software (version
11.0; Stata Corp, College Station, TX).
Results
Between 2003 and 2008, 1294 patients were identified as
meeting our study criteria. 1080 patients were ultimately
deemed eligible and included in descriptive analyses,
while incomplete pathological reports led to a small
number of additional exclusions. The subsequent multi-
variable modeling was base on 1075 patients, representing
83.1% of all eligible RP’s. Baseline characteristics of
patients undergoing RP are in Table 1. Fifteen surgeons
were divided according to their fellowship training and
academic affiliation resulting in three groups: FTA (n = 2),
NFTA (n = 3) and NA (n = 10). The average number of
annual RP’s per group was: FTA 20.5 (range: 13.4-27.6),
NFTA 4.3 (range: 0.2-11.4) and NA 12.1 (range: 0.2-51.6).
7 of 15 surgeons averaged less than 5 RP’s per year (2 of 3
within NFTA group and 5 of 10 within the NA group). In
our cohort, the majority of RP’s were performed in non-
academic centers (70.1%). The median age of the study
population was 62 years. The majority of patients had
organ-confined disease (71.5%) with a Gleason Sum of 7
(60.5%). 3.1% of patients had positive lymph nodes on finalTable 1 Patient characteristics (n = 1080)
All groups (%) FTA, n=238 (22.0)
Age* 62 (9.3) 60 (8.4)
Pathological Stage
pT2 772 (71.5) 160 (67.2)
pT3a 168 (15.6) 39 (16.4)
pT3b 121 (11.2) 34 (14.3)
pT4 19 (1.8) 5 (2.1)
Gleason Sum
≤ 6 295 (27.4) 64 (26.9)
7 653 (60.7) 147 (61.8)
≥ 8 127 (11.8) 27 (11.3)
Node Status
Positive 30 (3.1) 12 (5.4)
Negative 945 (96.9) 210 (94.6)
*Median (inter-quartile range).pathology. Overall PSM rates for organ confined disease
were 28.1%, 49.2% and 47.9% for FTA, NFTA and NA
groups accordingly.
On univariable analysis, age, pathological stage, Gleason
score, and surgeon group were all statistically significant
predictors of PSM (Table 2). Multivariable results are pre-
sented in Table 3. Surgeon volume was an independent
predictor of margin positivity, with low and medium
volumes being associated with lower rates of PSM
(p = 0.0166). Pathological stage and Gleason sum were
also independent predictors of PSM (p = 0.0004 and
p < 0.0001, respectively). After controlling for surgeon
volume, pathological stage and Gleason sum, the surgeon
group remained independently associated with PSM
(p < 0.0001). Overall, NFTA surgeons were associated with
a higher rate of PSM than FTA surgeons (OR 2.5, 95% CI:
1.44 – 4.35, p = 0.001). Similarly, NA urologists were also
associated with a higher rate of PSM following RP
compared to the FTA group (OR 2.1, 95% CI: 1.53 – 2.88,
p < 0.001). The difference between NFTA and NA urolo-
gists was not significant (OR =1.09; 95% CI 0.64 - 1.88,
p = 0.492).
Discussion
In our population-based cohort, we have shown that sur-
geon group was an independent predictor of obtaining
PSM following RP, after adjusting for annual volume,
pathological stage, and Gleason sum. RP is a complex pro-
cedure that has a steep learning curve associated with it
(>250 cases) [22]. Individual surgeon experience and annual
volume are important variables that have been previously
shown to be associated with PSM [3-12]. Interestingly, in a
small, prospective, cohort study, two newly graduated
surgeons who completed formal urological oncologySurgeon affiliation (%)
NFTA, n=85 (7.9) NA, n=757 (70.1) p-value
62 (8.6) 64 (9.0) <0.01
0.38
65 (76.5) 547 (72.3)
14 (16.5) 115 (15.2)
6 (7.1) 81 (10.7)
0 (0.0) 14 (1.9)
0.04
16 (19.3) 215 (28.5)
63 (75.9) 443 (58.8)
4 (4.8) 96 (12.7)
0.06
1 (1.3) 17 (2.5)
76 (98.7) 659 (97.5)
Table 2 Univariable analysis examining predictors of
positive surgical margins
Variable Odds ratio 95% CI P-value
Age 1.02 1.00 – 1.04 0.066
Surgeon affiliation <0.0001
FTA Reference
NFTA 1.83 1.11 – 3.02
NA 1.93 1.43 – 2.60
Pathological stage <0.0001
pT2 Reference
pT3a 2.36 1.67 – 3.34
pT3b 2.08 1.41 – 3.09
pT4 1.76 0.70 – 4.42
Gleason score (sum) <0.0001
≤6 Reference
7 2.04 1.54 – 2.72
≥8 3.46 2.24 – 5.36
Node status 0.053
Negative Reference
Positive 2.09 0.97 – 4.51
Volume of surgeries 0.113
Low (<10 cases/year) Reference
Med (10–20 cases/year) 0.83 0.54 – 1.28
High (>20 cases/year) 1.10 0.73 – 1.65
FTA: fellowship trained, academic; NFTA: non-fellowship trained, academic;
NA: non-academic.
Table 3 Multivariable analysis of factors predictive of
positive surgical margins
Variable Odds ratio 95% CI P-value
Surgeon affiliation <0.0001
FTA Reference -
NFTA 2.50 1.44 – 4.35
NA 2.10 1.53 – 2.88
Surgical volume 0.0170
High (>20 cases/year) Reference -
Medium (10–20 cases/year) 0.65 0.487 – 0.878
Low (<10 cases/year) 0.77 0.503 – 1.199
Pathological stage 0.0004
pT2 Reference -
pT3a 2.08 1.45 – 2.99
pT3b 1.63 1.06 – 2.53
pT4 1.51 0.58 – 3.91
Gleason score <0.0001
≤6 Reference -
7 1.90 1.41 – 2.56
≥8 2.66 1.64 – 4.31
FTA: fellowship trained, academic; NFTA: non-fellowship trained, academic;
NA: non-academic.
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showed that their results were comparable to results of RP’s
performed by very experienced surgeons in larger series
[21]. In this study, their first 66 consecutive patients under-
going RP were assessed from a tertiary, academic referral
center. Their overall PSM rate was commendable at 14%
while achieving a 94% 5-year biochemical, disease free sur-
vival rate. The author’s highlight that a strong urological
residency combined with their surgically intense (approxi-
mately 87 RP’s) clinical fellowship likely enhanced their
proficiency in performing RP. As a growing number of uro-
logic oncology fellowship trained surgeons enter academia,
the impact of oncology-specific fellowship training on
pathological outcomes is important to address as it repre-
sents an objective means of evaluating this additional train-
ing. Certainly, the concept that specialization may improve
outcomes is not novel, yet our study is the first to show in
a population-based design, that urological oncology fellow-
ship training is associated with improved rates of PSM. The
reason for this is unclear however others have suggested
this difference may be due to improved surgical technique
or perhaps that those who undergo fellowship training are
more critical of their own surgical approach [23].In addition, there is a paucity of population-based lit-
erature examining pathological outcomes following RP
and we have also shown that PSM rates are likely
higher in “real-life” which may suggest that studies
based out of tertiary cancer centers may not necessarily
hold true at the population-based level. In another
population-based study, the rate of PSM after RP in
organ-confined disease was 33% [18], comparatively
lower than our NFA and NA groups in our study, but
higher than our FTA group. However, even amongst ex-
perienced surgeons, the rates of PSM shows consider-
able variability, ranging from 10-48% [7]. Many studies
examining PSM rates are from tertiary cancer centers
and may not truly represent the “real world” which en-
dorses the importance of conducting population-based
studies. Regardless, the rates of PSM in our study are
high. The reasons for this are unclear but are likely
multi-factorial. One explanation may be the significant
heterogeneity within each surgeon groups. Almost half
of surgeons included in this population averaged less
than 5 RP’s per year (2 of 3 NFTA surgeons, and 5 of
10 NA surgeons) that may have affected outcomes, par-
ticularly given the small group sizes. Their inclusion
adds variability to the results, but highlights the “real-
world” urologic practice. In fact, a study based out of
the UK revealed that 54% of 212 urologic surgeons per-
formed less than 10 RP’s per year, in keeping with our
results [24]. Similarly, there were four surgeons (2
Nayak et al. BMC Urology 2014, 14:82 Page 5 of 6
http://www.biomedcentral.com/1471-2490/14/82NFTA and 2 NA) who stopped performing RP’s midway
through the study period around the same time that the
FTA surgeons volume began to increase which may
suggest a generational change in practice that may be
confounded by the fellowship training. Although experience
is an invaluable asset in performing RP, we were unable to
account for this in our analysis.
There are several limitations to our study. Firstly, a
significant proportion of patients (16.9%) were excluded
from our analysis due to unavailable pathological re-
ports. The inclusion of these missing patients poten-
tially could affect our models and outcomes. However,
for a population-based study, the inclusion of over 80%
of patients may also be viewed as strength, as other
similar studies have drawn conclusions from a notably
smaller proportion of patients [18]. Another perceived
limitation of our study may be the lack of follow-up to
assess disease-specific and overall survival. Data avail-
ability precluded this. However, the study was not de-
signed to assess clinical outcomes but rather to examine
differences in PSM rates. Others have already shown that
PSM may be a surrogate for oncological outcomes
[7,13,15-18]. In contrast to previously published literature,
we also found that low and medium volume surgeon
groups were associated with reduced PSM. This may be
due to the relatively small number of surgeons practicing
in this region (n = 15), making the results for each group
easily influenced by a limited number of individuals. In
fact, although the FTA group consisted of surgeons with
moderate-high average annual RP volumes (median 21.5,
range 13.4-27.6), overall 70% of RP’s were performed in
non-academic centers where the average number of RP’s
per year ranged from 0.2-51.6. In addition, our study did
not have central pathology review. The histo-pathological
interpretation of RP specimens is inherently subjective, yet
although inter-observer variability exists, it has been
shown that concordance between expert urological pa-
thologists regarding PSM are excellent [25]. Others have
also shown that the location, length, and Gleason sum of
the PSM has prognostic significance [26], and that not all
PSM carry the same risk of developing biochemical recur-
rence [27,28]. Unfortunately, data constraints prevented
us from assessing this. Further, we did not have data on
other potentially confounding variables such as nerve-
sparing status, prostate volume, tumor volume or patient
factors including body-mass index or comorbidities. The
majority of RP’s described within this study were by
traditional open approach and may not apply to contem-
porary, minimally invasive techniques. Additionally, func-
tional outcomes are another measure of successful surgery
but were unable to be captured in the present study.
Finally, our data apply to groups of urologists categorized
by fellowship training and academic practice, and should
not be extrapolated to individual surgeon performance.Despite these limitations, our study shows that in this
population-based cohort treated in the contemporary
PSA era, academic surgeons with fellowship training
were associated with a reduced risk of PSM. This finding
highlights an important surgeon related factor that
should be considered but requires further investigation
in larger studies.
Conclusion
After adjusting for pathological stage, Gleason sum and
surgeon volume, RP performed by oncology fellowship
trained urologists were associated with significantly
lower rates of PSM. This training may provide additional
knowledge and skills to shorten the learning curve asso-
ciated with RP. Furthermore, our results suggest that
surgeon level of training be considered in future studies
examining outcomes post-RP.
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